PL3335723T3 - Pojedyncze domeny zmienne immunoglobuliny do zastosowania w sposobach leczenia TTP - Google Patents

Pojedyncze domeny zmienne immunoglobuliny do zastosowania w sposobach leczenia TTP

Info

Publication number: PL3335723T3
Authority: PL; Poland
Prior art keywords: methods; variable domains; single variable; immunoglobulin single; treating ttp
Prior art date: 2014-06-16

Application number

PL18153673.1T

Other languages

English (en)

Inventor

Christian DUBY

Original Assignee

Ablynx Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-06-16

Filing date

2015-06-16

Publication date

2022-07-18

2015-06-16 Application filed by Ablynx Nv filed Critical Ablynx Nv

2022-07-18 Publication of PL3335723T3 publication Critical patent/PL3335723T3/pl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Hematology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

PL18153673.1T 2014-06-16 2015-06-16 Pojedyncze domeny zmienne immunoglobuliny do zastosowania w sposobach leczenia TTP PL3335723T3 (pl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
NL2013007A NL2013007B1 (en)	2014-06-16	2014-06-16	Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
US201462030817P	2014-07-30	2014-07-30

Publications (1)

Publication Number	Publication Date
PL3335723T3 true PL3335723T3 (pl)	2022-07-18

Family

ID=51541255

Family Applications (5)

Application Number	Title	Priority Date	Filing Date
PL18153676T PL3332800T3 (pl)	2014-06-16	2015-06-16	Pojedyncze domeny zmienne immunoglobuliny do stosowania w sposobach leczenia TTP
PL18153674.9T PL3335724T3 (pl)	2014-06-16	2015-06-16	Pojedyncze domeny zmienne immunoglobuliny do zastosowania w sposobach leczenia TTP
PL18153671T PL3366305T3 (pl)	2014-06-16	2015-06-16	Sposoby leczenia ttp za pomocą pojedyńczych immunoglobulinowych domen zmiennych i ich zastosowania
PL15729829T PL3154569T3 (pl)	2014-06-16	2015-06-16	Pojedyncze domeny zmienne immunoglobuliny do zastosowania w leczeniu TTP
PL18153673.1T PL3335723T3 (pl)	2014-06-16	2015-06-16	Pojedyncze domeny zmienne immunoglobuliny do zastosowania w sposobach leczenia TTP

Family Applications Before (4)

Application Number	Title	Priority Date	Filing Date
PL18153676T PL3332800T3 (pl)	2014-06-16	2015-06-16	Pojedyncze domeny zmienne immunoglobuliny do stosowania w sposobach leczenia TTP
PL18153674.9T PL3335724T3 (pl)	2014-06-16	2015-06-16	Pojedyncze domeny zmienne immunoglobuliny do zastosowania w sposobach leczenia TTP
PL18153671T PL3366305T3 (pl)	2014-06-16	2015-06-16	Sposoby leczenia ttp za pomocą pojedyńczych immunoglobulinowych domen zmiennych i ich zastosowania
PL15729829T PL3154569T3 (pl)	2014-06-16	2015-06-16	Pojedyncze domeny zmienne immunoglobuliny do zastosowania w leczeniu TTP

Country Status (15)

Country	Link
US (5)	US10858445B2 (pl)
EP (6)	EP3335724B1 (pl)
JP (3)	JP6688746B2 (pl)
KR (2)	KR102403388B1 (pl)
CN (1)	CN106559985A (pl)
AU (2)	AU2015276237B2 (pl)
CA (1)	CA2952103A1 (pl)
ES (5)	ES2843642T3 (pl)
IL (1)	IL249540B (pl)
NL (1)	NL2013007B1 (pl)
PL (5)	PL3332800T3 (pl)
PT (5)	PT3335724T (pl)
RU (1)	RU2704444C2 (pl)
SG (2)	SG10201811109PA (pl)
WO (1)	WO2015193326A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL2013007B1 (en)	2014-06-16	2016-07-05	Ablynx Nv	Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
CN107340225B (zh) *	2017-07-13	2019-07-05	徐州医科大学	一种基于流式细胞术检测血小板受体GPIba胞外段酶切的方法
MY204220A (en)	2018-02-06	2024-08-16	Ablynx Nv	Methods of treating initial episode of ttp with immunoglobulin single variable domains
US20230405096A1 (en) *	2020-11-18	2023-12-21	Green Cross Corporation	Adamts13 variant having increased escaping rate or activity against autoantibody
EP4402165A1 (en)	2021-09-17	2024-07-24	The United States of America, as represented by the Secretary, Department of Health and Human Services	Synthetic humanized llama nanobody library and use thereof to identify sars-cov-2 neutralizing antibodies
CN118715246A (zh) *	2021-12-10	2024-09-27	李人浩	结合血管性血友病因子(vwf)a1结构域或自动抑制模块的多肽、变体及其用途

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB335768A (en)	1929-10-24	1930-10-02	Jacoviac Maurice	Improvements in protecting devices for gramophone disc records
US4399216A (en)	1980-02-25	1983-08-16	The Trustees Of Columbia University	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en)	1980-02-25	1993-01-12	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en)	1980-02-25	1987-01-06	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5043429B1 (en)	1987-05-01	1997-10-14	Scripps Research Inst	Protein fragments containing factor VIII binding domain of von willebrand factor
WO1990005144A1 (en)	1988-11-11	1990-05-17	Medical Research Council	Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
EP0656946B2 (en)	1992-08-21	2010-03-31	Vrije Universiteit Brussel	Immunoglobulins devoid of light chains
US5827690A (en)	1993-12-20	1998-10-27	Genzyme Transgenics Corporatiion	Transgenic production of antibodies in milk
US6329516B1 (en)	1997-04-28	2001-12-11	Fmc Corporation	Lepidopteran GABA-gated chloride channels
EP1157119A1 (en)	1999-02-05	2001-11-28	Rijksuniversiteit Leiden	Method of modulating metabolite biosynthesis in recombinant cells
IL147920A0 (en)	1999-08-02	2002-08-14	Keygene Nv	Method for generating cgmmv resistant plants, genetic constructs, and the obtained cgmmv-resistant plants
US20060073141A1 (en)	2001-06-28	2006-04-06	Domantis Limited	Compositions and methods for treating inflammatory disorders
ATE512364T1 (de)	2002-08-07	2011-06-15	Ablynx Nv	Modulation der blutplättchen-adhäsion basierend auf dem oberflächen-exponierten beta-switch loop des blutplättchen-glycoproteins ib-alpha
AU2003284891A1 (en)	2002-10-23	2004-05-13	Ludwig Institute For Cancer Research	A34 and a33-like 3 dna, proteins, antibodies thereto and methods of treatment using same
NZ540771A (en)	2003-01-10	2009-05-31	Ablynx Nv	Recombinant VHH single domain antibody from camelidae against von willebrand factor (vWF) or against collagen
RU2524129C2 (ru)	2003-01-10	2014-07-27	Аблинкс Н.В.	Терапевтические полипептиды, их гомологи, их фрагменты и их применение для модуляции агрегации, опосредованной тромбоцитами
US7461263B2 (en)	2003-01-23	2008-12-02	Unspam, Llc.	Method and apparatus for a non-revealing do-not-contact list system
CA2535550A1 (en)	2003-08-12	2005-03-03	William M. Yarbrough	Treatment for acne vulgaris and method of use
US7270976B2 (en) *	2004-07-19	2007-09-18	American Diagnostica, Inc.	Methods for measuring ADAMTS13 activity and protein on platelets and in plasma
US7563443B2 (en)	2004-09-17	2009-07-21	Domantis Limited	Monovalent anti-CD40L antibody polypeptides and compositions thereof
BRPI0518151A2 (pt)	2004-10-13	2009-06-16	Ablynx Nv	polipetìdeos contra amiloide-beta, ácido nucléico que codifica tal polipetìdeo, composição compreendendo tal polipetìdeo, método para produzir um polipetìdeo e uso do mesmo
ATE473446T1 (de)	2005-01-14	2010-07-15	Ablynx Nv	Verfahren und testvorrichtungen zur unterscheidung verschiedener formen von krankheiten und leiden, die durch thrombocytopenia und/oder durch spontane interaktionen zwischen dem von-willebrand-faktor und plättchen gekennzeichnet sind
CN101213214B (zh) *	2005-05-20	2014-06-25	埃博灵克斯股份有限公司	针对冯威勒布兰特因子的单一结构域vhh抗体
EP2057191A1 (en)	2006-08-18	2009-05-13	Ablynx N.V.	Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
JP2010518839A (ja)	2007-02-21	2010-06-03	アブリンクスエン．ヴェー．	血管内皮増殖因子に指向性を有するアミノ酸配列、及び過度の及び／もしくは病的な血管形成又は血管新生を特徴とする症状及び疾患を治療するためにこれを含むポリペプチド
CN101796072B (zh)	2007-05-24	2014-09-24	埃博灵克斯股份有限公司	用于治疗骨疾病和病症的针对rank-l的氨基酸序列以及包括其的多肽
WO2009115614A2 (en)	2008-03-21	2009-09-24	Ablynx Nv	Von willebrand factor specific binders and methods of use therefor
EP3011953A1 (en)	2008-10-29	2016-04-27	Ablynx N.V.	Stabilised formulations of single domain antigen binding molecules
EP2346900A1 (en)	2008-10-29	2011-07-27	Wyeth LLC	Methods for purification of single domain antigen binding molecules
WO2011067160A1 (en)	2009-12-01	2011-06-09	Ablynx Nv	Von willebrand factor specific binding agents and uses thereof
HRP20251174T1 (hr) *	2010-11-05	2025-11-21	Novartis Ag	Postupci za liječenje psorijatičnog artritisa uporabom il-17 antagonista
CN108210889A (zh)	2011-06-10	2018-06-29	百深有限责任公司	通过施用重组vwf治疗凝血疾病
PE20141522A1 (es)	2011-08-17	2014-11-17	Glaxo Group Ltd	Proteinas y peptidos modificados
NL2013007B1 (en)	2014-06-16	2016-07-05	Ablynx Nv	Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
MY204220A (en)	2018-02-06	2024-08-16	Ablynx Nv	Methods of treating initial episode of ttp with immunoglobulin single variable domains

2014
- 2014-06-16 NL NL2013007A patent/NL2013007B1/en active
2015
- 2015-06-16 EP EP18153674.9A patent/EP3335724B1/en active Active
- 2015-06-16 ES ES18153671T patent/ES2843642T3/es active Active
- 2015-06-16 PT PT181536749T patent/PT3335724T/pt unknown
- 2015-06-16 ES ES18153673T patent/ES2915473T3/es active Active
- 2015-06-16 PT PT181536764T patent/PT3332800T/pt unknown
- 2015-06-16 PL PL18153676T patent/PL3332800T3/pl unknown
- 2015-06-16 EP EP18153676.4A patent/EP3332800B1/en active Active
- 2015-06-16 EP EP15729829.0A patent/EP3154569B1/en active Active
- 2015-06-16 PL PL18153674.9T patent/PL3335724T3/pl unknown
- 2015-06-16 PL PL18153671T patent/PL3366305T3/pl unknown
- 2015-06-16 ES ES18153676T patent/ES2831865T3/es active Active
- 2015-06-16 SG SG10201811109PA patent/SG10201811109PA/en unknown
- 2015-06-16 JP JP2016573549A patent/JP6688746B2/ja active Active
- 2015-06-16 KR KR1020177001152A patent/KR102403388B1/ko active Active
- 2015-06-16 PT PT157298290T patent/PT3154569T/pt unknown
- 2015-06-16 EP EP18153673.1A patent/EP3335723B1/en active Active
- 2015-06-16 CN CN201580040020.4A patent/CN106559985A/zh active Pending
- 2015-06-16 PT PT181536715T patent/PT3366305T/pt unknown
- 2015-06-16 EP EP18153671.5A patent/EP3366305B1/en active Active
- 2015-06-16 ES ES18153674T patent/ES2924199T3/es active Active
- 2015-06-16 PT PT181536731T patent/PT3335723T/pt unknown
- 2015-06-16 CA CA2952103A patent/CA2952103A1/en not_active Abandoned
- 2015-06-16 EP EP22172948.6A patent/EP4059513A1/en not_active Withdrawn
- 2015-06-16 AU AU2015276237A patent/AU2015276237B2/en active Active
- 2015-06-16 PL PL15729829T patent/PL3154569T3/pl unknown
- 2015-06-16 US US15/319,467 patent/US10858445B2/en active Active
- 2015-06-16 KR KR1020227012546A patent/KR102568585B1/ko active Active
- 2015-06-16 RU RU2017100077A patent/RU2704444C2/ru active
- 2015-06-16 ES ES15729829T patent/ES2881331T3/es active Active
- 2015-06-16 SG SG11201610488QA patent/SG11201610488QA/en unknown
- 2015-06-16 WO PCT/EP2015/063493 patent/WO2015193326A1/en not_active Ceased
- 2015-06-16 PL PL18153673.1T patent/PL3335723T3/pl unknown
2016
- 2016-12-13 IL IL249540A patent/IL249540B/en unknown
2018
- 2018-01-26 US US15/881,055 patent/US20180155443A1/en not_active Abandoned
- 2018-01-26 US US15/881,003 patent/US10919980B2/en active Active
- 2018-01-26 US US15/880,870 patent/US20180155440A1/en not_active Abandoned
- 2018-01-26 US US15/880,978 patent/US12269893B2/en active Active
2020
- 2020-01-30 JP JP2020014229A patent/JP7105260B2/ja active Active
2021
- 2021-05-03 AU AU2021202747A patent/AU2021202747B2/en active Active
2022
- 2022-07-11 JP JP2022110921A patent/JP2022160431A/ja active Pending

Also Published As

Publication number	Publication date
ES2881331T3 (es)	2021-11-29
EP3335723A1 (en)	2018-06-20
IL249540B (en)	2021-09-30
RU2017100077A (ru)	2018-07-12
HK1256730A1 (en)	2019-10-04
ES2843642T3 (es)	2021-07-19
PL3335724T3 (pl)	2022-09-19
JP7105260B2 (ja)	2022-07-22
RU2019131713A (ru)	2019-11-11
ES2915473T3 (es)	2022-06-22
PL3154569T3 (pl)	2021-11-02
EP4059513A1 (en)	2022-09-21
NL2013007B1 (en)	2016-07-05
ES2924199T3 (es)	2022-10-05
KR20170015513A (ko)	2017-02-08
US20180155440A1 (en)	2018-06-07
CA2952103A1 (en)	2015-12-23
EP3335724B1 (en)	2022-06-22
HK1258508A1 (en)	2019-11-15
EP3154569A1 (en)	2017-04-19
PT3335723T (pt)	2022-05-20
CN106559985A (zh)	2017-04-05
AU2021202747B2 (en)	2024-02-15
KR102568585B1 (ko)	2023-08-18
KR20220053040A (ko)	2022-04-28
EP3366305A1 (en)	2018-08-29
EP3335723B1 (en)	2022-03-30
US10919980B2 (en)	2021-02-16
SG11201610488QA (en)	2017-01-27
US12269893B2 (en)	2025-04-08
AU2015276237B2 (en)	2021-02-25
EP3335724A1 (en)	2018-06-20
WO2015193326A1 (en)	2015-12-23
EP3332800A1 (en)	2018-06-13
RU2017100077A3 (pl)	2018-12-25
ES2831865T3 (es)	2021-06-09
US20170210822A1 (en)	2017-07-27
US10858445B2 (en)	2020-12-08
KR102403388B1 (ko)	2022-06-03
JP2022160431A (ja)	2022-10-19
SG10201811109PA (en)	2019-01-30
EP3154569B1 (en)	2021-04-21
AU2015276237A1 (en)	2017-01-19
US20180155443A1 (en)	2018-06-07
PT3335724T (pt)	2022-08-02
JP6688746B2 (ja)	2020-04-28
JP2020097600A (ja)	2020-06-25
EP3366305B1 (en)	2020-11-18
US20180155442A1 (en)	2018-06-07
PT3332800T (pt)	2020-11-19
EP3332800B1 (en)	2020-08-26
PT3154569T (pt)	2021-06-22
PL3366305T3 (pl)	2021-06-14
PT3366305T (pt)	2020-12-21
US20180155441A1 (en)	2018-06-07
RU2704444C2 (ru)	2019-10-28
AU2021202747A1 (en)	2021-05-27
JP2017519762A (ja)	2017-07-20
PL3332800T3 (pl)	2021-04-19
IL249540A0 (en)	2017-02-28
HK1256731A1 (en)	2019-10-04

Publication	Publication Date	Title
IL281755A (en)	2021-05-31	Enhanced variable complexes of immunoglobulins
IL247898A0 (en)	2016-11-30	Anti-ox40 antibodies and methods of use
IL252008A0 (en)	2017-06-29	Methods for producing bispecific domains, variants of antibodies and their use
IL250724A0 (en)	2017-04-30	Methods for treating multiple myeloma with immunomodulatory compounds in combination with antibodies
IL247699A0 (en)	2016-11-30	Preparations and methods for the treatment of kidney disorders
PT3335723T (pt)	2022-05-20	Domínios variáveis únicos de imunoglobulina para utilização em métodos de tratamento da ptt
IL265568A (en)	2019-05-30	Methods for treating TIM-3 elevation
HK1236434A1 (en)	2018-03-29	Methods of treating ttp with immunoglobulin single variable domains and uses thereof